Astellas Pharma Inc. ended its partnership Friday with South San Francisco’s Theravance Inc. around the antibiotic Vibativ.
The decision ends an up-and-down partnership between the companies, including production problems at a contractor manufacturer in Ohio in November that halted manufacturing and caused a shortage of the drug.
No comments:
Post a Comment